Spectral Medical Inc.

Spectral Medical Inc. develops theranostic solutions aimed at treating endotoxic septic shock. The company's primary products include the Endotoxin Activity Assay (EAA™) for rapid detection of endotoxin activity and Toraymyxin™ for extracorporeal hemoadsorption therapy to remove endotoxins from the bloodstream. Spectral Medical focuses on the critical care market, targeting healthcare providers and institutions dealing with sepsis, and operates primarily in North America. Its business model is centered on advancing therapeutic options through clinical trials and regulatory approvals.